Bruce H. Morimoto

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Adam L. Boxer, Anthony E. Lang, Murray Grossman et al. · The Lancet Neurology · 2014 · 282 citations · Full text

Placebo-controlled Phase 2/3, Progressive Supranuclear Palsy, Rehabilitation +3

Induction and expression of long- and short-term neurosecretory potentiation in a neural cell line

Bruce H. Morimoto, D E Koshland · Neuron · 1990 · 152 citations

Brain Circuitry, Neurophysiology, Physiology +10

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Bruce H. Morimoto, Don Schmechel, Joe Hirman et al. · Dementia and Geriatric Cognitive Disorders · 2013 · 111 citations

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

Sheila M. Fleming, Caitlin Mulligan, Franziska Richter et al. · Molecular and Cellular Neuroscience · 2010 · 72 citations

Molecular Neuroscience, Degenerative Pathology, Protein Misfolding +8

Excitatory amino acid uptake and N-methyl-D-aspartate-mediated secretion in a neural cell line.

Bruce H. Morimoto, Daniel E. Koshland · Proceedings of the National Academy of Sciences · 1990 · 52 citations · Full text

Synaptic Transmission, Neurotransmission, Neural Cell Line +21